In the era of molecularly driven therapies, offering sequential targeted treatment options in ALK and ROS1-positive NSCLC, re-characterization of the tumor via repeated biopsies has become an established procedure and was carried out in 50% of patients in the routine setting. This evidence concerns the gene ROS1 and neoplasm.